Abstract
The aim was to determine whether outcome of unrelated donor transplantation for severe aplastic anemia has improved in recent years and whether this is due to patient selection or better transplant technology. We analyzed 498 patients transplanted during 1990–2005. By running univariate regression models dichotomizing year of transplantation we defined 1998 as the year of the most significant change in survival. Five-year survival increased from 32±8% before 1998 to 57±8% after 1998 (P<0.0001). When comparing the cohort before (n=149) and after 1998 (n=349), there were no differences except for older age, and more frequent use of PBSCs, after 1998. High-resolution HLA typing data were unavailable. After 1998, there was less graft failure (11 vs 26%, P<0.0001), less acute GvHD (cumulative incidence 28 vs 37%, P=0.02) and less chronic GvHD (22 vs 38%, P=0.004). In multivariate analyses adjusting for differences in age, HLA-mismatch, performance score and time to transplantation, there was no change in the year of transplant effect (relative risk of death in transplants after 1998: 0.44 (95% confidence interval 0.33–0.59)). There is no evidence for patient selection to explain significantly improved survival in patients transplanted after 1998. We speculate that this is due to better donor matching.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Passweg JR, Socie G, Hinterberger W, Bacugalupo A, Biggs JC, Camitta B et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997; 90: 858–864.
Stucki A, Leisenring W, Sandmaier BM, Sanders J, Anasetti C, Storb R . Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood 1998; 92: 2742–2749.
Ades l, Mary JY, Robin M, Ferry C, Porcher R, Esperou H et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004; 103: 2490–2497.
Locatelli F, Bruno B, Zecca M, Van Lint MT, McCann S, Arcese W et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of GITMO/EBMT randomized trial. Blood 2000; 96: 1690–1697.
Champlin RE, Pérez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E et al. Bone marrow transplantation for aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007; 109: 4582–4585.
Marsh JC, Ball SE, Barbyshire P, Gordon-Smith EC, Keidan AJ, Martin A et al. Guidelines for the diagnosis and management of acquired aplastic anemia. Br J Haematol 2003; 123: 782–801.
Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007; 91: 11–18.
Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg JR et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy—The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000; 37: 69–80.
Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000; 96: 1931–1934.
Young NS, Calado RT, Scheinberg P . Current concepts on the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509–2519.
Passweg JR, Perez WS, Eapen M, Camitta BM, Gluckmann E, Hinterberger W et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 2006; 37: 641–649.
Speck B, Zwaan FE, van Rood JJ, Eernisse JG . Allogeneic bone marrow transplantation in a patient with aplastic anemia using a phenotypically HL-A-identical unrelated donor. Transplantation 1973; 16: 24–28.
Wagner JL, Deeg HJ, Seidel K, Anasetti C, Doney K, Sanders J et al. Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. Transplantation 1996; 61: 54–61.
Lohrmann HP, Dietrich M, Goldmann SF, Kristensen T, Fliedner TM, Abt C et al. Bone marrow transplantation for aplastic anemia from a HL-A and MLC-identical unrelated donor. Blut 1975; 31: 347–354.
Duquesnoy RJ, Zeevi A, Marrari M, Hackbarth S, Camitta B . Bone marrow transplantation for severe aplastic anemia using a phenotypically HLA-identical, SB-compatible unrelated donor. Transplantation 1983; 35: 566–571.
Camitta B, Ash R, Menitov J, Murray K, Lwaton C, Hunter J et al. Bone marrow transplantation for children with severe aplastic anemia: use of donors other than HLA-identical siblings. Blood 1989; 74: 1852–1857.
Hows JM, Yin JL, Marsh J, Swirsky D, Jones L, Apperley JF et al. Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood 1986; 68: 1322–1328.
Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593–602.
Margolis D, Camitta B, Pietryga D, Keever-Taylor C, Baxter-Lowe LA, Pierce K et al. Unrelated donor bone marrow transplantation to treat severe aplastic anemia in children and young adults. Br J Haematol 1996; 94: 65–72.
Kojima S, Inaba J, Yoshimi Ay, Takahashi Y, Watanabe N, Kudo K et al. Unrelated donor marrow transplantation in children with severe aplastic anemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol 2001; 114: 706–711.
Klein JP, Rizzo JD, Zhang MJ, Keiding N . Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: regression modeling. Bone Marrow Transplant 2001; 28: 1001–1011.
Cox DR . Regression models and life tables. J Roy Statist Soc Ser B Metho 1972; 34: 187–220.
Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovic A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923–1930.
Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT et al. Engraftment and survival after unrelateddonor bone marrow transplantation: a report from the national marrow donor program. Blood 2000; 96: 4096–4102.
Maury S, Balère-Appert ML, Chir Z, Boiron JM, Galambrun C, Yakouben K et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 2007; 92: 589–596.
Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002; 100: 799–803.
Deeg HJ, Seidel K, Casper J, Anasetti C, Davies S, Gajeweski JL et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who had failed immunosuppressive therapy. Biol Blood Marrow Transplant 1999; 5: 243–252.
Benesch M, Urban C, Sykora KW, Schwinger W, Zintl F, Lackner H et al. Transplantation of highly purified CD34+ progenitor cells from alternative donors in children with refractory severe aplastic anemia. Br J Haematol 2004; 125: 58–63.
Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001; 7: 208–215.
Deeg HJ, O'Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006; 108: 1485–1491.
Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socié G, Maury S et al. Fludarabine, cyclophosphamide and antithymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT SAA working party. Bone Marrow Transplant 2005; 36: 947–950.
Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006; 12: 1277–1284.
Acknowledgements
This study was supported by the Stiftung für Hämatologische Forschung, Basel, Switzerland.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Viollier, R., Socié, G., Tichelli, A. et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 41, 45–50 (2008). https://doi.org/10.1038/sj.bmt.1705894
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705894
Keywords
This article is cited by
-
Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia
Annals of Hematology (2021)
-
Comparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia
Bone Marrow Transplantation (2020)
-
Updated Guidelines for the Treatment of Acquired Aplastic Anemia in Children
Current Oncology Reports (2018)
-
Allogeneic hematopoietic cell transplantation for severe aplastic anemia: similar long-term overall survival after transplantation with related donors compared to unrelated donors
Bone Marrow Transplantation (2016)
-
Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia
International Journal of Hematology (2016)